PR

Paul Rennie

Paradigm Biopharmaceuticals Limited | Executive Director, Managing Director, Executive Chairman
Mr. Rennie has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. His experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their Director of business development. He also led the commercialisation of Recaldent a novel biopharmaceutical arising from research at the dental school, University of Melbourne. He took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. He worked in a number of positions with Mesoblast Ltd. He was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company.

Company and Roles

Company
Title
Tenure
Since
PAR
Paradigm Biopharmaceuticals Limited
  • Executive Director
  • Managing Director
  • Executive Chairman
12yrs, 5mthMay 2014

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
PAR
Paradigm Biopharmaceuticals Limited
30/06/268,322,31812,487,107606,043N/A
25/08/231,090,753N/A5,600,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
PAR
Paradigm Biopharmaceuticals Limited
29/06/26
Sell
600,000$0.165$99,000As advised by the company
PAR
Paradigm Biopharmaceuticals Limited
18/06/26
Buy
529,410$0.180$95,293Participation in share purchase plan
PAR
Paradigm Biopharmaceuticals Limited
02/06/26
Buy
352,940$0.170$60,000Participation in share purchase plan
PAR
Paradigm Biopharmaceuticals Limited
02/06/26
Transfer
8,545,848$0.155$1,324,606Off-market transfer
PAR
Paradigm Biopharmaceuticals Limited
02/06/26
Transfer
8,545,848$0.155$1,324,606Off-market transfer